News - Lucentis, Analgesia

Filter

Current filters:

LucentisAnalgesia

Popular Filters

1 to 25 of 59 results

Executive Q&A: Bob Radie, chief executive and president of Egalet

Executive Q&A: Bob Radie, chief executive and president of Egalet

11-04-2014

In an interview with The Pharma Letter, Egalet Corporation’s chief executive Bob Radie discusses the…

AnalgesiaChemistryChief executiveCombination productsEgalet CorpEgalet CorporationInterviewsPharmaceuticalSevere chronic painUSA

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Study: Half of veterans prescribed medical opioids continue to use them chronically

Study: Half of veterans prescribed medical opioids continue to use them chronically

07-03-2014

A study of nearly 1 million veterans who receive opioids to treat painful conditions found that more…

AnalgesiaHealthcarePharmaceuticalResearchUSA

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Novartis gets fourth indication, DME, for Lucentis in Japan

24-02-2014

Swiss drug major Novartis says it has received approval from Japanese regulatory bodies for a fourth…

Asia-PacificJapanLucentisNovartisOphthalmicsPharmaceuticalRegulation

FDA says Durect’s pain relief drug Posidur needs additional safety studies

FDA says Durect’s pain relief drug Posidur needs additional safety studies

13-02-2014

US drugmaker Durect Corp says that the US Food and Drug Administration has issued a Complete Response…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

NICE final guidance gives green light to Lucentis for CNV

NICE final guidance gives green light to Lucentis for CNV

27-11-2013

The UK’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

Altus signs $4 million agreement with Zogenix to license Zohydro ER

04-11-2013

Altus Pharmaceuticals has entered into an agreement with Zogenix to develop abuse deterrent formulations…

AnalgesiaLicensingNorth AmericaPharmaceuticalZogenixZohydro

Orexo’s Zubsolv could take market share from Suboxone, report suggests

Orexo’s Zubsolv could take market share from Suboxone, report suggests

30-10-2013

Edison Equity Research analysts say that expected new clinical data from Swedish drug developer Orexo…

AnalgesiaFinancialMarkets & MarketingNorth AmericaOrexo ABPharmaceuticalReckitt BenckiserZubsolv

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Zogenix shares leap after FDA approval for Zohydro ER

Zogenix shares leap after FDA approval for Zohydro ER

28-10-2013

Shares of Zogenix rocketed on Friday after the US Food and Drug Administration approved Zohydro ER extended-release…

AnalgesiaNorth AmericaPharmaceuticalRegulationZogenixZohydro

FDA calls for reclassification of codeine combo medications to stricter schedules

FDA calls for reclassification of codeine combo medications to stricter schedules

25-10-2013

The US Food and Drug Administration has indicated that it wants to see the classification of codeine-containing…

AnalgesiaHydrocodone Bitartrate and AcetaminophenNorth AmericaPharmaceuticalRegulation

NICE gives green light to Novartis’ Lucentis for eye condition

NICE gives green light to Novartis’ Lucentis for eye condition

25-10-2013

NICE has issued final draft guidance recommending Novartis' Lucentis for people with pathological myopia.

EuropeLucentisNovartisOphthalmicsPharmaceuticalRegulation

Pfizer to continue Remoxy pain relief development

Pfizer to continue Remoxy pain relief development

24-10-2013

US pharma giant Pfizer will continue the development program for Remoxy Extended-Release Capsules CII,…

AnalgesiaNorth AmericaPfizerPharmaceuticalRemoxyResearch

Iroko’s pain relief drug effective at low doses

Iroko’s pain relief drug effective at low doses

22-10-2013

Iroko Pharmaceuticals has announced that the US Food and Drug Administration has approved Zorvolex capsules…

AnalgesiaIrokoNorth AmericaPharmaceuticalRegulationZorvolex

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

21-10-2013

Pfizer has announced mixed results from two Phase IIIb studies of Lyrica capsules CV in patients with…

AnalgesiaLyricaNorth AmericaPfizerPharmaceuticalResearch

UK’s medicines watchdog recalls five Wockhardt medicines

UK’s medicines watchdog recalls five Wockhardt medicines

18-10-2013

The UK’s Medicines and Healthcare products Regulatory Agency has recalled five medicines made by Indian…

AnalgesiaDiabetesEuropeGliclazidePharmaceuticalProductionRegulationWockhardt

Positive new data for Novartis drug Lucentis across four indications

Positive new data for Novartis drug Lucentis across four indications

27-09-2013

Novartis has presented new clinical and real world data for its ophthalmic agent Lucentis in more than…

EuropeLucentisNovartisOpthalmicsPharmaceuticalResearch

BIA warns that UK government pricing proposals would damage UK biotech

20-08-2013

The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…

AvastinBayerEuropeEyleaFinancialLucentisPharmaceuticalPoliticsPricingRegeneronRoche

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Novartis' Lucentis first drug approved in EU for myopic choroidal neovascularization

05-07-2013

The European Commission has granted Swiss drug major Novartis (NOVN: VX) a new indication for Lucentis…

EuropeLucentisNovartisOphthalmicsPharmaceuticalRegulation

1 to 25 of 59 results

Back to top